These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15455193)

  • 21. Vertebral fractures: a hidden problem of osteoporosis.
    Haczynski J; Jakimiuk A
    Med Sci Monit; 2001; 7(5):1108-17. PubMed ID: 11535963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial.
    Arantes HP; Gimeno SG; Chiang AY; Bilezikian JP; Lazaretti-Castro M
    Arch Endocrinol Metab; 2016 Feb; 60(1):54-9. PubMed ID: 26909483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
    J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
    Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.
    Black DM; Thompson DE
    Int J Clin Pract Suppl; 1999 Apr; 101():46-50. PubMed ID: 12669740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoride and bone: a second look. No use in osteoporosis.
    Prescrire Int; 1998 Aug; 7(36):110-1. PubMed ID: 10342949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos).
    Papaioannou A; Joseph L; Ioannidis G; Berger C; Anastassiades T; Brown JP; Hanley DA; Hopman W; Josse RG; Kirkland S; Murray TM; Olszynski WP; Pickard L; Prior JC; Siminoski K; Adachi JD
    Osteoporos Int; 2005 May; 16(5):568-78. PubMed ID: 15517191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
    Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.
    Genant HK; Jergas M; Palermo L; Nevitt M; Valentin RS; Black D; Cummings SR
    J Bone Miner Res; 1996 Jul; 11(7):984-96. PubMed ID: 8797120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study).
    Sanfélix-Genovés J; Reig-Molla B; Sanfélix-Gimeno G; Peiró S; Graells-Ferrer M; Vega-Martínez M; Giner V
    Bone; 2010 Sep; 47(3):610-6. PubMed ID: 20601286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of postmenopausal osteoporosis in Germany: estimations from a disease model.
    Gauthier A; Kanis JA; Jiang Y; Dreinhöfer K; Martin M; Compston J; Borgström F; Cooper C; McCloskey E
    Arch Osteoporos; 2012; 7():209-18. PubMed ID: 23196864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive review of treatments for postmenopausal osteoporosis.
    Häuselmann HJ; Rizzoli R
    Osteoporos Int; 2003 Jan; 14(1):2-12. PubMed ID: 12577179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mild prevalent and incident vertebral fractures are risk factors for new fractures.
    Roux C; Fechtenbaum J; Kolta S; Briot K; Girard M
    Osteoporos Int; 2007 Dec; 18(12):1617-24. PubMed ID: 17611706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.